Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2014 L.P. Mpm Sells 14,569 Shares of Stock

Posted by Stanley Muller on Aug 27th, 2026

Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) major shareholder Bioventures 2014 L.P. Mpm sold 14,569 shares of the stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $7.06, for a total transaction of $102,857.14. Following the completion of the sale, the insider directly owned 4,318,348 shares in the company, valued at approximately $30,487,536.88. The trade was a 0.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

On Tuesday, August 25th, Bioventures 2014 L.P. Mpm sold 26,522 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.54, for a total value of $199,975.88.
On Monday, August 24th, Bioventures 2014 L.P. Mpm sold 21,623 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.34, for a total transaction of $158,712.82.

Entrada Therapeutics Trading Down 8.1%

TRDA opened at $7.00 on Thursday. Entrada Therapeutics, Inc. has a twelve month low of $5.02 and a twelve month high of $16.45. The business’s 50 day moving average is $7.08 and its 200-day moving average is $9.36. The stock has a market cap of $272.58 million, a PE ratio of -1.77 and a beta of -0.26.

Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The company had revenue of $0.90 million for the quarter, compared to analysts’ expectations of $2.32 million. Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. As a group, analysts forecast that Entrada Therapeutics, Inc. will post -4.03 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on TRDA shares. Guggenheim reduced their price objective on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Monday, June 8th. Roth Capital reaffirmed a “buy” rating and issued a $11.00 target price on shares of Entrada Therapeutics in a research note on Wednesday, August 12th. HC Wainwright lowered shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. Finally, Weiss Ratings downgraded Entrada Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 13th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $17.75.

Read Our Latest Stock Report on TRDA

Institutional Trading of Entrada Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Odyssean LLC acquired a new stake in Entrada Therapeutics during the 2nd quarter worth approximately $230,000. Nantahala Capital Management LLC purchased a new stake in shares of Entrada Therapeutics during the second quarter valued at approximately $2,212,232,000. Public Employees Retirement System of Ohio acquired a new position in shares of Entrada Therapeutics in the 2nd quarter valued at approximately $276,000. Bank of America Corp DE bought a new position in Entrada Therapeutics during the 2nd quarter worth approximately $426,000. Finally, 5AM Venture Management LLC acquired a new stake in Entrada Therapeutics during the second quarter worth about $29,854,949,000. 86.39% of the stock is currently owned by hedge funds and other institutional investors.

Entrada Therapeutics Company Profile

(Get Free Report)

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.